Project 1: Characterization of the Antibody Response to SARS-CoV-2 in Lung Cancer Patients

项目 1：肺癌患者对 SARS-CoV-2 抗体反应的表征

基本信息

批准号：
10222309
负责人：
Florian Krammer
金额：
$ 139.63万
依托单位：
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-30 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10222309
关键词：
2019-nCoV Address Advocate Age Antibodies Antibody Response Antiviral Agents Binding Biological Assay COVID-19 COVID-19 pandemic COVID-19 vaccine Cancer Control Cancer Patient Cells Clinical Clinical Sciences Clinical Trials Collaborations Complement Coronavirus Data Science Core Demographic Impact Development Epithelial Cells Ethnic Origin Fc Receptor Future Gender General Population Generations Glycoproteins Hamsters Histology Immune Immune response Immunity Incidence Individual Infection Kinetics Knowledge Longevity Lung Malignant Neoplasms Malignant neoplasm of lung Mediating Modeling Patients Persons Policies Population Predisposition Preparation Race Regimen Role Serologic tests Serological Smoking History Smoking Status Specimen Statistical Data Interpretation Testing Vaccinated Vaccination Vaccines Viral Viral Antigens Viral Proteins Virus Vulnerable Populations Work base cancer cell cancer therapy case control comorbidity comparative cytokine demographics design infection rate insight inter-individual variation mortality neutralizing antibody patient response power analysis prospective protective efficacy receptor response seropositive trait translational scientist vaccine candidate vaccine response vaccine trial virology

2019-nCoV Address Advocate Age Antibodies Antibody Response Antiviral Agents Binding Biological Assay COVID-19 COVID-19 pandemic COVID-19 vaccine Cancer Control Cancer Patient Cells Clinical Clinical Sciences Clinical Trials Collaborations Complement Coronavirus Data Science Core Demographic Impact Development Epithelial Cells Ethnic Origin Fc Receptor Future Gender General Population Generations Glycoproteins Hamsters Histology Immune Immune response Immunity Incidence Individual Infection Kinetics Knowledge Longevity Lung Malignant Neoplasms Malignant neoplasm of lung Mediating Modeling Patients Persons Policies Population Predisposition Preparation Race Regimen Role Serologic tests Serological Smoking History Smoking Status Specimen Statistical Data Interpretation Testing Vaccinated Vaccination Vaccines Viral Viral Antigens Viral Proteins Virus Vulnerable Populations Work base cancer cell cancer therapy case control comorbidity comparative cytokine demographics design infection rate insight inter-individual variation mortality neutralizing antibody patient response power analysis prospective protective efficacy receptor response seropositive trait translational scientist vaccine candidate vaccine response vaccine trial virology

展开

项目摘要

PROJECT 1: ABSTRACT Current information indicates that, in persons without cancer, natural infection with SARS-CoV-2 as well as vaccination with COVID-19 vaccine candidates induce antibody responses to the spike protein of the virus which should be protective against future infection. Lung cancer patients who become infected with SARS- CoV-2 appear to develop severe COVID-19 with a high (35-40%) mortality rate indicating we urgently need to plan for vaccine trials in this vulnerable population. Currently we have major knowledge gaps to fill in preparation for such vaccine studies. These include: is there a higher incidence of SARS-CoV-2 in lung cancer patients compared to the general population? Do lung cancer patients mount a comparable antibody response in terms of quantity, quality, and longevity to people without lung cancer? Equally important are information in lung cancer patients on the role of age, gender, smoking status, histology, and types of treatment for lung cancer on both SARS-CoV-2 infection rate and generation of antibody responses. Through prospective analyses of lung cancer cases (N= 1,000) and matched controls (N = 1,000) this Project “Characterization of the Antibody Response to SARS-CoV-2 in Lung Cancer Patients” will provide answers to these important questions through study of 4 specific aims and the use of our U54 Administrative, Clinical, and Data Sciences Cores. Aim 1: Characterize the incident, magnitude and functionality of the antibody response to SARS-CoV-2 in lung cancer patients versus non-lung cancer controls. Aim 2: Compare the longevity of the antibody response against SARS-CoV-2 in lung cancer patients versus non-lung cancer controls. Aim 3: Evaluate the impact of patient demographics and cancer-associated clinical factors on the antibody response in lung cancer patients. And Aim 4: Characterize antibody responses to SARS-CoV-2 vaccination in lung cancer patients versus non-lung cancer controls. The patient serology specimens will also be studied for viral neutralizing functionality in collaboration with U54 Project 2. We have assembled a world-class team of lung cancer clinical translational investigators, serology and virology experts, and patient advocates to address these key issues. The results of this Project will have a significant impact on lung cancer patient management during the COVID-19 pandemic, and even greater impact on designing optimal SARS-CoV-2 vaccination regimens for lung cancer patients.

项目1：摘要当前信息表明，在没有癌症的人中，使用SARS-COV-2以及 COVID-19疫苗候选疫苗接种诱导对病毒的尖峰蛋白的抗体反应应保护未来感染。感染SAR的肺癌患者 COV-2似乎发展了严重的Covid-19，其死亡率高（35-40％），这表明我们迫切需要计划在此脆弱人群中进行疫苗试验。目前，我们有重大的知识差距可以填补为这种疫苗研究做准备。其中包括：SARS-COV-2在肺癌中是否有更高的事件患者与普通人群相比？肺癌患者是否会安装可比的抗体反应在没有肺癌的人的数量，质量和寿命方面？同样重要的是信息肺癌患者在年龄，性别，吸烟状况，组织学和肺部治疗类型上的作用 SARS-COV-2感染率和抗体反应的产生。通过潜在的对肺癌病例的分析（n = 1,000）和匹配的对照（n = 1,000）该项目“表征肺癌患者对SARS-COV-2的抗体反应”将为这些重要的答案提供答案通过研究4个特定目标以及使用U54行政，临床和数据的问题科学核心。目标1：表征抗体反应的事件，大小和功能肺癌患者与非肺癌对照的SARS-COV-2。目标2：比较肺癌患者与非肺癌对照中对SARS-COV-2的抗体反应。目标3：评估患者人口统计学和癌症相关临床因素对抗体反应的影响在肺癌患者中。 AIM 4：表征肺中对SARS-COV-2疫苗接种的抗体反应癌症患者与非肺癌对照。患者血清学标本也将研究病毒与U54项目2合作中和功能。我们组建了一个世界一流的肺部团队癌症临床翻译研究者，血清学和病毒学专家以及患者倡导者解决这些关键问题。该项目的结果将对肺癌患者管理产生重大影响在19日期大流行期间，甚至对设计最佳SARS-COV-2疫苗接种的影响更大肺癌患者的方案。